Human and viral nucleoside/nucleotide kinases involved in antiviral drug activation: Structural and catalytic properties

Antiviral Research

Volumn 86, Issue 1, 2010, Pages 101-120

  Deville Bonne, Dominique ^a   El Amri, Chahrazade ^a   Meyer, Philippe ^b   Chen, Yuxing ^c   Agrofoglio, Luigi A ^d   Janin, Joël ^e  

^a SORBONNE UNIVERSITÉ   (France)

^b LABORATOIRE D ENZYMOLOGIE ET BIOCHIMIE STRUCTURALES   (France)

^c UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^d UNIVERSITÉ D'ORLÉANS   (France)

^e INSTITUTE FOR INTEGRATIVE BIOLOGY OF THE CELL I2BC   (France)

Author keywords

Adenylate kinase; Brivudin; Bromovinyldeoxyuridine; Deoxycytidine kinase; Deoxyguanosine kinase; Ganciclovir; Herpes simplex virus; Lamivudine; Nm23; Nucleoside diphosphate kinase; Phosphoglycerate kinase; Telbivudine; Tenofovir; Thymidine kinase; Thymidylate kinase; Vaccinia virus

Indexed keywords

5 (2 BROMOVINYL) 2' DEOXYURIDINE; ACICLOVIR; ADEFOVIR; ADENYLATE KINASE; ANTIVIRUS AGENT; CIDOFOVIR; DEOXYGUANOSINE KINASE; DNA POLYMERASE; GANCICLOVIR; GUANYLATE KINASE; IDOXURIDINE; LAMIVUDINE; NUCLEOSIDE DIPHOSPHATE KINASE; PHOSPHOGLYCERATE KINASE; STAVUDINE; TELBIVUDINE; TENOFOVIR DISOPROXIL; THYMIDINE KINASE; THYMIDYLATE SYNTHASE; URIDINE PHOSPHATE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AMINO ACID SEQUENCE; CATALYSIS; CYTOMEGALOVIRUS INFECTION; DRUG APPROVAL; DRUG STRUCTURE; ENZYME KINETICS; ENZYME PHOSPHORYLATION; ENZYME SPECIFICITY; ENZYME SUBSTRATE; HEPATITIS B; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYDROGEN BOND; PHOSPHATE TRANSPORT; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RETINITIS; REVIEW; VARICELLA ZOSTER VIRUS; VIRUS INFECTION;

ANTIVIRAL AGENTS; HUMANS; NUCLEOSIDES; NUCLEOTIDES; PHOSPHOTRANSFERASES; PRODRUGS; VIRUSES;

DNA VIRUSES; HERPES; HUMAN IMMUNODEFICIENCY VIRUS; SIMPLEXVIRUS; VACCINIA VIRUS;

EID: 77952263334     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.02.001     Document Type: Review

References (207)

1. Aden J., Wolf-Watz M. NMR identification of transient complexes critical to adenylate kinase catalysis. J. Am. Chem. Sci. 2007, 1219:14003-14012.
2. Admiraal S.J., Schneider B., Meyer P., Janin J., Véron M., Deville-Bonne D., Herschlag D. Nucleophilic activation by positioning in phosphoryl tranfer catalyzed by nucleoside diphosphate kinase. Biochemistry 1999, 38:4701-4711.
3. Aktary Z., Chapman K., Lam L., Lo A., Ji C., Graham K., Cook L., Li L., Mackey J.R., Pasdar M. Plakoglobin interacts with and increases the protein levels of metastasis suppressor Nm23-H2 and regulates the expression of Nm23-H1. Oncogene 2010, January 25 [Epub ahead of print].
4. Alexandre J.A., Roy B., Topalis D., Pochet S., Perigaud C., Deville-Bonne D. Enantioselectivity of human AMP, dTMP and UMP-CMP kinases. Nucleic Acids Res. 2007, 35:4895-4904.
5. Ardiani A., Sanchez-Bonilla M., Black M.E. Fusion enzymes containing HSV1-thymidine kinase mutants and guanylate kinase enhance prodrug senitivity in vitro and in vivo. Cancer Gene Ther. 2009, 17:86-96.
6. Arner E.S.J., Eriksson S. Mammalian deoxyribonucleoside kinases. Pharmacol. Ther. 1995, 67:155-186.
7. Auvynet C., Topalis D., Caillat C., Munier-Lehmann H., Seclaman E., Balzarini J., Agrofoglio L.A., Kaminsky P.A., Meyer P., Deville-Bonne D., El-Amri C. Exploring vaccinia virus TMP kinase and human GMP kinase specificities for several alkylated or oxydized dGMP analogs. Biochem. Biophys. Res. Commun. 2009, 388:6-11.
8. Balzarini J., Bohman C., De Clercq E. Differential mechanism of cytostatic effect of [E]-5-(2-bromovinyl)-2′-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type2. J. Biol. Chem. 1993, 268:6332-6337.
9. Balzarini J., De Clercq E., Ayusawa D., Seno T. Murine mammary FM3A carcinome cells transformed with the herpes simplex virus type 1 thymidine kinase gene are highly sensitive to the growth-inhibitory properties of (E)-5-(2-bromovinyl)-2′-deoxyuridine and related compounds. FEBS Lett. 1985, 185:95-100.
10. Balzarini J., Hao Z., Herdewijn P., Johns D.G., De Clercq E. Intracellular metabolism and mechanism of anti-retrovirus action of 9-(2-phosphonylmethoxyethyl)adenine, a potent anti-human immunodeficiency virus compound. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:1499-1503.
11. Balzarini J., Liekens S., Esnouf R., De Clercq E. The A167Y mutation converts the herpes simplex virus type 1 thymidine kinase into a guanosine analogue kinase. Biochemistry 2002, 41:6517-6524.
12. Balzarini J., Liekens S., Solaroli N., El Omari K., Stammers D.K., Karlsson A. Engineering of a single conserved amino acid residue of herpes simplex virus type 1 thymidine kinase allows a predominant shift from pyrimidine to purine nucleoside phosphorylation. J. Biol. Chem. 2006, 281:19273-19279.
13. Balzarini J., Van Herrewege Y., Vanham G. Metabolic activation of nucleoside and nucleotide reverse transcriptase inhibitors in dendritic and Langerhans cells. AIDS 2002, 16:2159-2163.
14. Balzarini J., Zhu C., De Clercq E., Pérez-Pérez M.-J., Chamorro C., Camarasa M.-J., Karlsson A. Novel ribofuranosylnucleoside lead compounds for potent and selective inhibitors of mitochondrial thymidine kinase-2. Biochem. J. 2000, 351:167-171.
15. Barbier O., Turgeon D., Girard C., Green M.D., Tephly T.R., Hum D.W., Bélanger A. 3′-Azido-3′-deoxythymidine (AZT) is glucuronidated by human UDP-glucuronosyltransferase 2B7 (UGT2B7). Drug Metab. Dispos. 2000, 28:497-502.
16. Barroso J.F., Elholm M., Flatmark T. Tight binding of deoxyribonucleoside triphosphates to human thymidine kinase 2 expressed in E. coli. Purification and partial purification to its dimeric and tetrameric forms. Biochemistry 2003, 42:15158-15169.
17. Barth R.F., Yang W., Wu G., Swindall M., Byun Y., Narayanasamy S., Tjarks W., Tordoff K., Moeschberger M.L., Eriksson S., Binns P.J., Riley K.J. Thymidine kinase 1 as a molecular target for boron neutron therapy of brain tumors. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:17493-17497.
18. Baughman C., Morin-Leisk J., Lee T. Nucleoside diphosphate kinase B (NDPKB) scaffolds endoplamic reticulum membranes in vitro. Exp. Cell Res. 2008, 314:2702-2714.
19. Belanger A.S., Caron P., Harvey M., Zimmerman P.A., Mehlotra R.K., Guillemette C. Glucuronidation of the antiretroviral drug efavirenz by UGT2B7 and in vitro investigation of drug-drug interaction with zidovudine. Drug Metab. Dispos. 2009, 37:1793-1796.
20. Benkovic S.J., Schray K.J. Chemical basis of biological phosphoryl transfer. The Enzymes 1968, vol. 8:201-238. Academic Press, New York.
21. Berg P., Joklik W.K. Enzymatic phosphorylation of nucleoside diphosphates. J. Biol. Chem. 1954, 210:657-672.
22. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., Bourne P.E. The protein data bank. Nucleic Acids Res. 2000, 28:235-242.
23. Bilitou A., Watson J., Bartner A., Ohnuma S. The NM23 family in development. Mol. Cell. Biochem. 2009, 329:17-33.
24. Bird L.E., Ren J., Wright A., Leslie K.D., Degreve B., Balzarini J., Stammers D.K. Crystal structure of varicella zoster virus thymidine kinase. J. Biol. Chem. 2003, 278:24680-24687.
25. Biron K.K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71:154-163.
26. Birringer M.S., Claus M.T., Folkers G., Kloer D.P., Schulz G.E., Scapozza L. Structure of a type II thymidine kinase with bound dTTP. FEBS Lett. 2005, 28:1376-1382.
27. Black M.E., Kokoris M.S., Sabo P. Herpes simplex virus-1 thymidine kinase mutants created by semi-random sequence mutagenesis improve prodrug-mediated tumor cell killing. Cancer Res. 2001, 61:3022-3026.
28. Black M.E., Newcomb T.G., Wilson H.M., Loeb L.A. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:3525-3529.
29. Blondin C., Serina L., Wiesmuller L., Gilles A.-M., Barzu O. Improved spectrophotometric assay of nucleoside monophosphate kinase activity using the pyruvate kinase/lactate dehydrogenase coupling system. Anal. Biochem. 1994, 220:219-221.
30. Boehme R. Phosphorylation of the antiviral precursor 9-(1,3-dihydroxy-2-propoxymethyl)guanine monophosphate by guanylate kinase isozymes. J. Biol. Chem. 1984, 259:12346-12349.
31. Boissan M., Dabernat S., Peuchant E., Schlattner U., Lascu I., Lacombe M.L. The mammalian Nm23/NDPK family: from metastasis control to cilia movement. **Mol. Cell. Biochem. 2009, 329:51-62.
32. -: creatine transition-state analogue complex. FEBS Lett. 2008, 582:3959-3965.
33. Both G.W. Recent progress in gene-directed enzyme prodrug therapy: an emerging cancer treatment. Curr. Opin. Mol. Ther. 2009, 4:421-432.
34. Bourdais J., Biondi R., Sarfati S., Guerreiro C., Lascu I., Janin J., Veron M. Cellular phosphorylation of anti-HIV nucleosides. J. Biol. Chem. 1996, 271:7887-7890.
35. Brown D.G., Visse R., Sandhu G., Davies A., Rizkallah P.J., Metitz C., Summers W.C., Sanderson M.R. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir. Nat. Struct. Biol. 1995, 2:876-881.
36. Brundiers R., Lavie A., Veit T., Reinstein J., Schlichting I., Ostermann N., Goody R.S., Konrad M. Modifying human thymidylate kinase to potentiate azidothymidine activation. J. Biol. Chem. 1999, 274:35289-35292.
37. Bunkoczi, G., Filippakopoulos, P., Debreczeni, J.E., Turnbull, A., Papagrigiriou, E., Savitsky, P., Colebrook, S., Von Delft, F., Arrowsmith, C., Edwards, A., Sundstrom, M., Weigelt, J., Knapp, S., 2005. Structure of human adenylate kinase. 2. Structural Genomics Consortium Oxford protein data bank code 2c9y.
38. Caillat C., Topalis D., Agrofoglio L.A., Pochet S., Balzarini J., Deville-Bonne D., Meyer P. Crystal structure of poxvirus thymidylate kinase: a dimerization with implications for antiviral therapy. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:16900-16905.
39. Candice L.W., Django S., Black M.E. The role of herpes simplex virus-1 thymidine kinase alanine 168 in substrate specificity. Open Biochem. J. 2008, 2:60-66.
40. Chen M.S., Prusoff W. Association of thymidylate kinase activity with pyrimidine deoxyribonucleoside kinase induced by herpes simplex virus. J. Biol. Chem. 1978, 235:1325-1327.
41. Chen Y., Gallois-Montbrun S., Schneider B., Veron M., Morera S., Deville-Bonne D., Janin J. Nucleotide binding to nucleoside diphosphate kinases: X-ray structure of human NDPK-A in complex with ADP and comparison to proteine kinases. J. Mol. Biol. 2003, 332:915-926.
42. Chen Y., Morera S., Pasti C., Augusti A., Solaroli N., Véron M., Janin J., Manfredini S. Adenosine phosphonoacetic acid is slowly metabolized by NDP kinase. Med. Chem. 2005, 1:529-536.
43. Chen Y.L., Lin D.W., Chang Z.F. Identification of a putative human mitochondrial thymidine monophosphate kinase associated with monocytic/macrophage terminal differenciation. Genes Cells 2008, 13:679-689.
44. Cheng Y.-C. l-Nucleoside analogues against cancer-causing viruses have potential in the prevention, delayed onset and treatment of viral associated cancers. Antiviral Chem. Chemother. 2001, 12(Suppl. 1):5-11.
45. Cheng Y.C., Dutschman G., De Clercq E., Jones A.S., Rahim S.G., Verhelst G., Walker R.T. Differential affinities of 5-(2-halogenovinyl)-2′-deoxyuridines for deoxythymidine kinases of various origins. Mol. Pharmacol. 1981, 20:230-233.
46. Christians F.C., Scapozza L., Crameri A., Folkers G., Stemmer W.P.C. Directed evolution of thymidine kinase for AZT phosphorylation using DNA family shuffling. Nat. Biotechnol. 1999, 17:259-264.
47. Cihlar T., Chen M.S. Identification of enzymes catalyzing two-step phosphorylation of cidofovir and the effect of cytomegalovirus infection on their activities in host cells. Mol. Pharmacol. 1996, 50:1502-1510.
48. Coen D.M., Schaffer P.A. Antiherpesvirus drugs: a promising spectrum of new drugs and drug targets. Nat. Rev. Drug Discov. 2003, 2:278-288.
49. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992, 256:1550-1552.
50. De Clercq E. Discovery and development of BVDU (brivudin) as a therapeutic for the treatment of herpes zoster. Biochem. Pharmacol. 2004, 68:2301-2315.
51. De Clercq E., Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat. Rev. Drug Discov. 2005, 4:928-940.
52. De Clercq E., Neyts J. Therapeutic potential of nucleoside/nucleotide analogues againt poxvirus infections. Rev. Med. Virol. 2004, 14:289-300.
53. Degrève B., Esnouf R., De Clercq E., Balzarini J. Selective abolishment of pyrimidine nucleoside kinase activity of herpes simplex virus type 1 thymidine kinase by mutation of alanine 167 to tyrosine. Mol. Pharmacol. 2000, 58:1326-1332.
54. Delaney W.E., Ray A.S., Yang H., Qi X., Xiong S., Zhu Y., Miller M.D. Intracellular metabolism and in vitro activity of tenofovir against hepatitis B virus. Antimicrob. Agents Chemother. 2006, 50:2471-2477.
55. DeLano W. The PyMOL Molecular Graphics System 2002, DeLano Scientific, Palo Alto, CA.
56. Deval J., Alvarez K., Selmi B., Bermond M., Boretto J., Guerreiro C., Mulard L., Canard L. Mechanistic insights into the suppression of drug resistance by human immunodeficiency virus type 1 reverse transcriptase using alpha-boranophosphate nucleoside analogs. J. Biol. Chem. 2005, 280:3838-3846.
57. Deville-Bonne D., Sellam O., Merola F., Lascu I., Desmadril M., Véron M. Phosphorylation of nucleoside diphosphate kinase at the active site studied by steady-state and time-resolved fluorescence. Biochemistry 1996, 35:14643-14650.
58. Dexheimer T.S., Carey S.S., Zuohe S., Gokhale V.M., Hu X., Murata L.B., Maes E.M., Weichsel A., Sun D., Meuillet E.J., Montfort W.R., Hurley L.H. NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III1. Mol. Cancer Ther. 2009, 8:1363-1377.
59. Dombrauckas J.D., Santarsiero B.D., Mesecar A.D. Structural basis for tumor pyruvate kinase M2 allosteric regulation and catalysis. Biochemistry 2005, 44:9417-9423.
60. Dotti G., Tian M., Savoldo B., Najjar A., Cooper L.J., Jackson J., Smith A., Mawlawi O., Uthamanthil R., Borne A., Brammer D., Paolillo V., Alauddin M., Gonzalez C., Steiner D., Decker W.K., Marini F., Kornblau S., Bollard C.M., Shpall E.J., Gelovani J.G. Repetitive noninvasive monitoring of HSV1-tk-expressing T cells intravenously infused into nonhuman primates using positron emission tomography and computed tomography with 18F-FEAU. Mol. Imaging 2009, 8:230-237.
61. Drake R.R., Mcmasters R., Krisa S., Hume S.D., Rechtin T.M., Saylors R.L., Chiang Y., Govindarajan R., Munshi N. Metabolism and activities of 3′-azido-2′,3′-dideoxythymidine and 2′,3′-didehydro-2′,3′-dideoxythymidine in herpesvirus thymidine kinase transduced T-lymphocytes. Antiviral Res. 1997, 35:177-185.
62. El Omari K., Solaroli N., Karlsson A., Balzarini J., Stammers D.K. Structure of vaccinia virus thymidine kinase in complex with dTTP: insights for drug design. BMC Struct. Biol. 2006, 6:22-31.
63. Eriksson S., Munch-Petersen B., Johansson K., Eklund H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59:1327-1346.
64. Feng J.Y., Parker W.B., Krajewski M.L., Deville-Bonne D., Veron M., Krishnan P., Cheng Y.-C., Borroto-Esoda K. Anabolism of amdoxovir: phosphorylation of dioxolane guanosine and its 5′-phosphates by mammalian phosphotransferases. Biochem. Pharmacol. 2004, 68:1879-1888.
65. Filippakopoulos, P., Bunkoczi, G., Jansson, A., Schreurs, A., Knapp, S., Edwards, A., Von Delft, F., Sundstrom, M., 2005. Crystal structure of human AK1A in complex with AP5A. Structural Genomics Consortium Oxford PDB code 1Z83.
66. Frangeul A., Barral K., Alvarez K., Canard B. In vitro suppression of K65R reverse transcritase-mediated tenofovir- and adefovir-5′-diphosphate resistance conferred by the boranophosphonate derivatives. Antimicrob. Agents Chemother. 2007, 51:3162-3167.
67. Franzolin E., Rampazzo C., Pérez-Pérez M.-J., Hernandez A.-I., Balzarini J., Bianchi V. Bromovinyl-deoxyuridine: a selective substrate for mitochondrial thymidine kinase in cell extracts. Biochem. Biophys. Res. Commun. 2006, 344:30-36.
68. Furman P.A., Fyfe J.A., St Clair M.H., Weinhold K., Rideout J.L., Freeman G.A., Nusinoff Lehrman S., Bolognesi D.P., Broder S., Mitsuya H., Barry D.W. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8333-8337.
69. Fyfe J.A. Differential phosphorylation of (E)-5-(2-bromovinyl)-2′-deoxyuridine monophosphate by thymidylate kinases from herpes simplex viruses types 1 and 2 and varicella zoster virus. Mol. Pharmacol. 1982, 21:432-437.
70. Fyfe J.A., Keller P.M., Furman P.A., Miller R.L., Elion G.B. Thymidine kinase from herpes simplex virus phosphorylates the new antiviral compound, 9-(2-hydroxyethoxymethyl)guanine. J. Biol. Chem. 1978, 253:8721-8727.
71. Gallois-Montbrun S., Chen Y., Dutartre H., Sophys M., Morera S., Guerreiro C., Schneider B., Mulard L., Janin J., Véron M., Deville-Bonne D., Canard B. Structural analysis of the activation of ribavirin analogs by NDP kinase: comparison with other ribavirin targets. Mol. Pharmacol. 2003, 63:538-546.
72. Gallois-Montbrun S., Faraj A., Seclaman E., Sommadossi J.-P., Deville-Bonne D., Véron M. Broad specificity of human phosphoglycerate kinase for antiviral nucleoside analogs. Biochem. Pharmacol. 2004, 68:1749-1756.
73. Gallois-Montbrun S., Schneider B., Chen Y., Giacomoni-Fernandes V., Mulard L., Morera S., Janin J., Deville-Bonne D., Véron M. Improving Nucleoside diphosphate kinase for antiviral nucleotide analogs activation. J Biol. Chem. 2002, 277:39953-39959.
74. Galmarini C.M., Clarke M.L., Jordheim L., Santos C.L., Cros E., Mackey J.R., Dumontet C. Resistance to gemcitabine in a human lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol. 2004, 4:8.
75. Garces E., Cleland W.W. Kinetic studies of yeast nucleoside diphosphate kinase. Biochemistry 1969, 8:633-640.
76. Gardberg A., Shuvalova L., Monnerjahn C., Konrad M., Lavie A. Structural basis for the dual thymidine and thymidylate kinase activity of herpes thymidine kinases. Structure 2003, 11:1265-1277.
77. Gardoni F. MAGUK proteins: new targets for pharmacological intervention in the glutamatergic synapse. Eur. J. Pharmacol. 2008, 585:147-152.
78. Gaubert G., Gosselin G., Boudou V., Imbach J.L., Eriksson S., Maury G. Low enantioselectiviies of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2′-deoxyadenosine,2′-deoxyguanosine and their analogs. Biochimie 1999, 81:1041-1047.
79. Georgiou G. Analysis of large libraries of protein mutants using flow cytometry. Adv. Protein Chem. 2000, 55:293-315.
80. Gerth M.L., Lutz S. Non-homologous recombinaison of deoxyribonucleoside kinases from human and Drosophila melanogaster yields human-like enzymes with novel activities. J. Mol. Biol. 2007, 370:742-751.
81. Gilles A.M., Presecan E., Vonica A., Lascu I. Structural characterization of the two polypeptide chains responsible for heterogeneity of the hexameric enzyme. J. Biol. Chem. 1991, 266:8784-8789.
82. Gondeau C., Chaloin L., Lallemand P., Roy B., Périgaud C., Barman T., Varga A., Vas M., Lionne C., Arold S.T. Molecular basis for the lack of enantioselectivity of human 3-phosphoglycerate kinase. Nucleic Acids Res. 2008, 36:3620-3629.
83. Gonin P., Xu Y., Milon L., Dabernat S., Morr M., Kumar R., Lacombe M.-L., Janin J., Lascu I. Catalytic mechanism of nucleoside diphosphate kinase investigated using nucleotide analogues, viscosity effects and X-ray crystallography. Biochemistry 1999, 38:7265-7272.
84. Gustafson E.A., Chillemi A.C., Sage D.R., Fingeroth J.D. The Epstein-Barr virus thymidine kinase does not phosphorylate ganciclovir or acyclovir and demonstrates a narrow substrate specificity compared to herpes simplex type 1 thymidine kinase. Antimicrob. Agents Chemother. 1998, 42:2923-2931.
85. Hazra S., Sabini E., Ort S., Konrad M., Lavie A. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry 2009, 48:1256-1263.
86. Heidelberger C., Chaudhuri N.P.D., Mooren D., Griesbach L., Duschinsky R., Schnitzer R., Pleven E., Scheiner J. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature 1957, 179:663-666.
87. Herrström S.A., Wang L.Y., Eriksson S. Substrate specificity of human recombinant mitochondrial 2′-deoxyguanosine kinase with cytostatic and antiviral purine and pyrimidine analogs. Mol. Pharmacol. 1998, 53:270-273.
88. Hible G., Daalova P., Gilles A.M., Cherfils J. Crystal structures of GMP kinase in complex with ganciclovir monophosphate and Ap5G. Biochimie 2006, 88:1157-1164.
89. Hible G., Renault L., Schaeffer F., Christova P., Radulescu A.Z., Evrin C., Gilles A.-M., Cherfils J. Calorimetric and crystallographic analysis of the oligomeric structure of Escherichia coli GMP kinase. J. Mol. Biol. 2005, 352:1044-1059.
90. Hida K., Hanes J., Ostermeier M. Directed evolution for drug and nucleic acid delivery. Adv. Drug Deliv. Rev. 2007, 59:1562-1578.
91. Hinds T.A., Compadre C., Hurlburt B.K., Drake R.R. Conservative mutations of glutamine-125 in herpes simplex virus type 1 thymidine kinase result in a ganciclovir kinase with minimal deoxypyrimidine kinase activities. Biochemistry 2000, 39:4105-4111.
92. Hsu C.-H., Hu R., Dutschman G.E., Yang G., Krishnan P., Tanaka H., Baba M., Cheng Y.-C. Comparison of the phosphorylation of 4′-ethynyl 2′,3′-dihydro 3′-deoxythymidine with that of other anti-human immunodeficiency virus thymidine analogs. Antimicrob. Agents Chemother. 2007, 51:1687-1693.
93. Hu R., Li L., Degreve B., Dutschman G.E., Lam W., Cheng Y.C. Behavior of thymidylate kinase toward monophosphate metabolites and its role in the metabolism of 1-(2′-deoxy-2′-fluoro-beta-l-arabinofuranosyl)-5-methyluracil (Clevudine) and 2′,3′-didehydro-2′,3′-dideoxythymidine in cells. Antimicrob. Agents Chemother. 2005, 49:2044-2049.
94. Huang S.H., Tang A., Drisco B., Zhang S.Q., Seeger R., Li C., Jong A. Human dTMP kinase: gene expression and enzymatic activity coinciding with cell cycle progression and cell growth. DNA Cell. Biol. 1994, 13:461-471.
95. Hutter M.C., Helms V. Phosphoryl transfer by a concerted reaction mechanism in UMP-CMP kinase. Protein Sci. 2000, 9:2225-2231.
96. Janin J., Deville-Bonne D. Nucleoside-diphosphate kinase: structural and kinetic analysis of reaction pathway and phosphohistidine intermediate. Methods Enzymol. 2002, 354:118-134.
97. Janin J., Dumas C., Moréra S., Xu Y., Meyer P., Chiadmi M., Cherfils J. Three-dimensional structure of nucleoside diphosphate kinase. J. Bioenerg. Biomembr. 2000, 32:215-225.
98. Jessen H.J., Schulz T., Balzarini J., Meier C. Bioreversible protection of nucleoside diphosphates. Angew. Chem. Int. Ed. Engl. 2008, 47:8719-8722.
99. Johansson K., Ramaswamy S., Ljungcrantz C., Knecht W., Piskur J., Munch-Petersen B., Eriksson S., Eklund H. Structural basis for substrate specificities of cellular deoxyribonucleoside kinases. Nat. Struct. Biol. 2001, 8:616-620.
100. Jordheim L.P., Dumontet C. Review of recent studies on resistance to cytotoxic deoxynucleoside analogues. Biochem. Biophys. Acta 2007, 1776:138-159.
101. Kamil J.P., Hume A.J., Jurak I., Kalejta R.F., Coen D.M. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:16823-16828.
102. Kandeel M., Ando T., Kitamura Y., Abdel-Aziz M., Kitade Y. Mutational, inhibitory and microcalorimetric analyses of Plasmodium falciparum TMP kinase. Implications for drug discovery. Parasitology 2009, 136:11-25.
103. Klumpp S., Krieglstein J. Reversible phosphorylation of histidine residues in proteins from vertebrates. Sci. Signal. 2009, 2:13.
104. Knecht W., Sandrini M.P., Johansson K., Eklund H., Munch-Petersen B., Piskur J. A few amino acid substitutions can convert deoxyribonucleoside kinase specificity from pyrimidines to purines. EMBO J. 2002, 21:1873-1880.
105. Koch K., Chen Y., Gallois-Montbrun S., Feng J.Y., Borroto-Esoda K., Deville-Bonne D., Janin J., Moréra S. Nucleoside diphosphate kinase and the activation of antiviral phosphonate analogs of nucleotides: binding mode and phosphorylation of tenofovir derivatives. Nucleosides Nucleotides Nucleic acids 2009, 28:776-792.
106. Kokoris M.S., Black M.E. Characterization of herpes simplex virus type 1 thymidine kinase mutants engineered for improved ganciclovir or acyclovir activity. Protein Sci. 2002, 11:2267-2272.
107. Kokoris M.S., Sabo P., Black M.E. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy. Anticancer Res. 2000, 20:959-963.
108. Kreimeyer A., Schneider B., Sarfati R., Faraj A., Sommadossi J., Véron M., Deville-Bonne D. NDP kinase reactivity towards 3TC nucleotides. Antiviral Res. 2001, 50:147-156.
109. Krishnan P., Fu Q., Lam W., Liou J.C., Dutschman G.E., Cheng Y.-C. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of l-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 2002, 277:5453-5459.
110. Krishnan P., Liou J.-Y., Cheng Y.-C. Phosphorylation of pyrimidine l-deoxynucleoside analog diphosphates: kinetics of phosphorylation and dephosphorylation of nucleoside analog diphosphates and triphosphates by 3-phosphoglycerate kinase. J. Biol. Chem. 2002, 277:31593-31600.
111. Larder B.A., Cheng Y.-C., Darby G. Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type-1. J. Gen. Virol. 1983, 64:523-532.
112. Lascu I., Gonin P. The catalytic mechanism of nucleoside diphosphate kinases. J. Bioenerg. Biomembr. 2000, 32:237-246.
113. Lavie A., Konrad M. Structural requirements for efficient phosphorylation of nucleotide analogs by human thymidylate kinase. Mini Rev. Med. Chem. 2004, 4:351-359.
114. Lavie A., Konrad M., Brundiers R., Goody R.S., Schlichting I., Reinstein J. Crystal structure of yeast thymidylate kinase complexed with the bisubstrate inhibitor P1-(5′-adenosyl) P5-(5′-thymidyl) pentaphosphate (TP5A) at 2.0 A resolution: implications for catalysis and AZT activation. Biochemistry 1998, 37:3677-3686.
115. Lavie A., Ostermann N., Brundiers R., Goody R.S., Reinstein J., Konrad M., Schlichting I. Structural basis for efficient phosphorylation of 3′-azidothymidine monophosphate by Escherichia coli thymidylate kinase. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:14045-14050.
116. Lavie A., Schlichting I., Vetter I.R., Konrad M., Reinstein J., Goody R.S. The bottleneck in AZT activation. Nat. Med. 1997, 3:922-924.
117. Lavie A., Su Y., Ghassemi M., Novak R.M., Caffrey M., Sekulic N., Monnerjahn C., Konrad M., Cook J.L. Restoration of the antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus by delivery of engineered thymidylate kinase to T cells. J. Gen. Virol. 2008, 89:1672-1679.
118. Lavie A., Vetter I.R., Konrad M., Goody R.S., Reinstein J., Schlichting I. Structure of thymidylate kinase reveals the cause behind the limiting step in AZT activation. Nat. Struct. Biol. 1997, 4:601-604.
119. Li Y., Spangenberg O., Paarman I., Konrad M., Lavie A. Structural basis for nucleotide-dependent regulation of membrane-associated guanylate kinase-like domains. J. Biol. Chem. 2002, 277:4159-4165.
120. Liou J.C., Dutschman G.E., Lam W., Jiang Z., Cheng Y.-C. Characterization of human UMP/CMP kinase and its phosphorylation of d- and l-form deoxycytidine analogue monophosphates. Cancer Res. 2002, 62:1624-1631.
121. Liu L., Li Y., Liotta D., Lutz S. Directed evolution of an orthogonal nucleoside analog kinase via fluorescence-activated cell sorting. Nucleic Acids Res. 2009, 37:4472-4481.
122. Mathé C., Gosselin G. l-Nucleoside enantiomers as antiviral drugs. Antiviral Res. 2006, 71:276-281.
123. Maughan D.W., Henkin J.A., Vigoreaux J.O. Concentrations of glycolytic enzymes and other cytosolic proteins in the diffusible fraction of a vertebrate muscle proteome. Mol. Cell. Proteomics 2005, 4:1541-1549.
124. Mazzon C., Rampazzo C., Scaini M.C., Gallinaro L., Karlsson A., Meier C., Balzarini J., Reichard P., Bianchi V. Cytosolic and mitochondrial deoxyribonucleotides: activity with substrate analogs, inhibitors and implications for therapy. Biochem. Pharmacol. 2003, 66:471-479.
125. Mehta A., Orchad S. Nucleoside diphosphate kinase (NDPK, NM23, AWD): recent regulatory advances in endocytosis, metastasis, psoriasis, insulin release, fetal erythroid lineage and heart failure; translational medicine exemplified. Mol. Cell. Biochem. 2009, 329:3-35.
126. Meyer P., Schneider B., Sarfati S., Deville-Bonne D., Guerreiro C., Boretto J., Janin J., Véron M., Canard B. Structural basis for activation of alpha-boranophosphate nucleotide analogues targeting drug-resistant reverse transcriptase. EMBO J. 2000, 19:3520-3529.
127. Michel D., Pavic I., Zimmermann A., Haupt E., Wunderlich K., Heuschmid M., Mertens T. The UL97 gene product of human cytomegalovirus is an early-late protein with a nuclear localization but is not a nucleoside kinase. J. Virol. 1996, 70:6340-6346.
128. Miller W.H., Miller R.L. Phosphorylation of acyclovir (acycloguanosine) monophosphate by GMP kinase. J. Biol. Chem. 1980, 255:7204-7207.
129. Miller W.H., Miller R.L. Phosphorylation of acyclovir diphosphate by cellular enzymes. Biochem. Pharmacol. 1982, 31:3879-3884.
130. Moolten F., Wells J.M. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 1990, 82:297-300.
131. Moréra S., Lacombe M.-L., Xu Y.W., LeBras G., Janin J. X-ray structure of human nucleoside diphosphate kinase B complexed with GDP at 2A resolution. Structure 1995, 3:1307-1374.
132. Moréra S., Lascu I., Dumas C., LeBras G., Briozzo P., Véron M., Janin J. Adenosine 5′-diphosphate binding and the active site of nucleoside diphosphate kinase. Biochemistry 1994, 33:459-467.
133. Moss B. Poxviridae and their replication. Virology 1990, 2079-2111. Raven Press Ltd., New York. B.N. Fields, D.M. Knipe (Eds.).
134. Munch-Petersen B., Cloos L., Tyrsted G., Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J. Biol. Chem. 1991, 266:9032-9038.
135. Naesens L., De Clercq E. Recent developments in herpesvirus therapy. Herpes 2001, 8:12-16.
136. Nallamothu G., Dammai V., Hsu T. Developmental function of Nm23/awd: a mediator of endocytosis. Mol. Cell. Biochem. 2009, 329:35-44.
137. Olsen M., Iverson B., Georgiou G. High-throughput screening of enzyme libraries. Curr. Opin. Biotechnol. 2000, 11:331-337.
138. Ostermann N., Schlichting I., Brundiers R., Konrad M., Reinstein J., Veit T., Goody R.S., Lavie A. Insights into the phosphoryltransfer mechanism of human thymidylate kinase gained from crystal structures of enzyme complexes along the reaction coordinate. Structure 2000, 8:629-642.
139. Ostermann N., Segura-Pena D., Meier C., Veit T., Monnerjahn C., Konrad M., Lavie A. Structures of human thymidylate kinase in complex with prodrugs: implications for the structure-based design of novel compounds. Biochemistry 2003, 42:2568-2577.
140. Pai E.F., Sachsenheimer W., Schirmer R.H., Schulz G.E. Substrate positions and induced-fit in crystalline adenylate kinase. J. Mol. Biol. 1977, 114:37-45.
141. Palmer D.H., Young L.S., Mautner V. Cancer gene-therapy: clinical trials. Trends Biotechnol. 2006, 24:76-82.
142. Pasti C., Gallois-Montbrun S., Munier-Lehmann H., Véron M., Gilles A.-M., Deville-Bonne D. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur. J. Biochem. 2003, 270:1784-1790.
143. Perozzo R., Jelesarov I., Bosshard H.R., Folkers G., Scapozza L. Compulsory order of substrate binding to herpes simplex virus type 1 thymidine kinase. J. Biol. Chem. 2000, 275:16139-16145.
144. Pilger B.D., Perozzo R., Alber F., Wurth C., Folkers G., Scapozza L. Substrate diversity of herpes simplex virus thymidine kinase: impact of the kinematics of the enzyme. J. Biol. Chem. 1999, 274:31967-31973.
145. Pontarin G., Gallinaro L., Ferraro P., Reichard P., Bianchi V. Origins of mitochondrial thymidine triphosphate: dynamics relations to cytosolic pools. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:12159-12164.
146. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapies. Mol. Aspects Med. 2007, 28:4-41.
147. Postel E.H., Berberich S.J., Flint S.J., Ferrone C.A. Human c-myc transcription factor PuF identified as nm23-H2 nucleoside diphosphate kinase, a candidate suppressor of tumor metastasis. Science 1993, 261:478-480.
148. Postel E.H., Wohlman I., Zou X., Juan T., Sun N., D'Agostin D., Cuellar M., Choi T., Notterman D.A., La Perle K.M. Targeted deletion of Nm23/nucleoside diphosphate kinase A and B reveals their requirement for definitive erythropoiesis in the mouse embryo. Dev. Dyn. 2009, 238:775-787.
149. Prichard M., Britt W.J., Daily S.L., Hartline C.B., Kern E.R. Human cytomegalovirus UL97 kinase is required for normal intranuclear distribution of pp65 and virion morphogenesis. J. Virol. 2005, 79:15494-15502.
150. Prichard M.N., Keith K.A., Johnson M.P., Harden E.A., McBrayer A., Luo M., Qiu S., Chattopadhyay D., Fan X., Torrence P.F., Kern E.R. Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob. Agents Chemother. 2007, 51:1795-1803.
151. Prusoff W.H. Discussion of the possible mechanisms of action of 5-iodo-2′-deoxyuridine and chymotrypsin in the treatment of herpes simplex keratitis. Trans. Am. Acad. Ophthalmol. Otolaryngol. 1963, 67:707-709.
152. Prusoff W.H., Bakhle Y.S., McCrea J.F. Incorporation of 5-iodo-2′-deoxyuridine into the deoxyribonucleic acid of vaccinia virus. Nature 1963, 199:1310-1311.
153. Puttick J., Baker E.N., Delbaere L.T. Histidine phosphorylation in biological systems. Biochem. Biophys. Acta 2008, 1784:100-105.
154. Rinaldo-Matthis A., Rampazzo C., Balzarini J., Reichard P., Bianchi V., Nordlund P. Crystal structures of the mitochondrial deoxyribonucleotidase in complex with two specific inhibitors. Mol. Pharmacol. 2004, 65:860-867.
155. Robbins B.L., Greenhaw J., Connelly M.C., Fridland A. Metabolic pathways for activation of the antiviral agent 9-(2-phosphonylmethoxyethyl)adenine in human lymphoid cells. Antimicrob. Agents Chemother. 1995, 39:2304-2308.
156. Rosengard A.M., Krutzsch H.C., Shearn A., Biggs J.R., Barker E., Margulies I.M., King C.R., Liotta L.A., Steeg P.S. Reduced Nm23/Awd protein in tumour metastasis and aberrant Drosophila development. Nature 1989, 342:177-180.
157. Sabini E., Hazra S., Konrad M., Lavie A. Nonenantioselectivity property of human deoxcytidine kinase explained by structures of the enzyme in complex with l- and d-nucleosides. J. Med. Chem. 2007, 50:3004-3014.
158. Sabini E., Ort S., Monnerjahn C., Konrad M., Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat. Struct. Biol. 2003, 10:513-519.
159. Sanchez Puch S.I., Mathet V.L., Porta M., Cuestas M.L., Oubina J.R., Videla C.M., Salomon H.E. Single and multiple mutations in the human cytomegalovirus UL97 gene and their relationship to the enzymatic activity of UL97 kinase for ganciclovir phosphorylation. Antiviral Res. 2009, 84:194-198.
160. Sato T., Neschadim A., Konrad M., Fowler D.H., Lavie A., Medin J.A. Engineered human TMPK/AZT as a novel enzyme/prodrug axis for suicide gene therapy. Mol. Ther. 2007, 15:962-970.
161. Schaertl S., Konrad M., Geeves M. Substrate specificity of human nucleoside diphosphate kinase revealed by transient kinatic analysis. J. Biol. Chem. 1998, 273:5662-5669.
162. Scheffzek K., Ahmadian M.R., Kabsch W., Wiesmüller L., Lautwein A., Schmitz F., Wittinghofer A. The Ras-GAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 1997, 277:333-338.
163. 2+ at 2.2Å: implications for water-mediated specificity. Biochemistry 1996, 35:9716-9727.
164. Schelling P., Folkers G., Scapozza L. A spectrophotometric assay for quantitative determination of kcat of herpes simplex virus type 1 thymidine kinase substrates. Anal. Biochem. 2001, 295:82-87.
165. Schlichting I., Reichstein J. Structures of the active conformations of UMP kinase from Dictyostelium discoideum suggest phosphoryl transfer is associative. Biochemistry 1997, 36:9290-9296.
166. Schlichting I., Reinstein J. pH influences fluoride coordination number of the AlFX phosphoryl transfer transition state analog. Nat. Struct. Biol. 1999, 6:721-725.
167. Schneider B., Biondi R., Sarfati R., Agou F., Guerreiro C., Deville-Bonne D., Véron M. The mechanism of phosphorylation of anti-HIV d4T by nucleoside diphosphate kinase. Mol. Pharmacol. 2000, 57:948-953.
168. Schneider B., Xu Y.W., Sellam O., Sarfati R., Janin J., Véron M., Deville-Bonne D. Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides. J. Biol. Chem. 1998, 273:11491-11497.
169. Segura-Pena D., Lichter J., Trani M., Konrad M., Lavie A., Lutz S. Quaternary structure change as a mechanism for the regulation of thymidine kinase 1-like enzymes. Structure 2007, 15:1555-1566.
170. Segura-Pena D., Sekulic N., Ort S., Konrad M., Lavie A. Substrate-induced conformational changes in human UMP/CMP kinase. J. Biol. Chem. 2004, 279:33882-33889.
171. Sekulic N., Shuvalova L., Spangenberg O., Konrad M., Lavie A. Structural characterization of the closed conformation of mouse guanylate kinase. J. Biol. Chem. 2002, 277:30236-30243.
172. Shafiee M., Griffon J.F., Gosselin G., Cambi A., Vincenzetti S., Vita A., Eriksson S., Imbach J.L., Maury G. A comparison of the enantioselectivities of human deoxycytidine kinase and human cytidine deaminase. Biochem. Pharmacol. 1998, 56:1237-1242.
173. Shewach D., Liotta D., Schinazi R. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 1993, 45:1540-1543.
174. Smee D.F., Sidwell R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antiviral Res. 2003, 57:41-52.
175. Smith K.M., Slugoski M.D., Cass C.E., Baldwin S.A., Karpinski E., Young J.D. Cation coupling properties of human concentrative nucleoside transporters hCNT1, hCNT2 and hCNT3. Mol. Membr. Biol. 2007, 24:53-64.
176. Smith R.F., Freyer M.W., Lewis E.A. Biophysical characterization of vaccinia virus thymidine kinase substrate utilization. J. Virol. Methods 2007, 142:151-158.
177. Spadari S., Maga G., Focher F., Ciarrochi G., Manservigi R., Arcamone F., Capobianco M., Carcuro A., Colonna F., Iotti S., Garbesi A. l-Thymidine is phosphorylated by herpes simplex virus type 1 thymidine kinase and inhibits viral growth. J. Med. Chem. 1992, 35:4214-4220.
178. Steeg P.S., Bevilacqua G., Kopper L., Thorgeirsson U.P., Talmadge J.E., Liotta L.A., Sobel M.E. Evidence for a novel gene associated with low tumor metastatic potential. J. Natl. Cancer Inst. 1988, 80:200-204.
179. Sullivan V., Talarico C.L., Stanat S.C., Davis M., Coen D.M., Biron K.K. A protein kinase homologue controls phosphorylation of ganciclovir in human cytomegalovirus-infected cells. Nature 1992, 358:162-164.
180. Tamm I., Eggers H. Specific inhibition of replication of animal viruses. Science 1963, 142:24-33.
181. Thorne S.H., Hwang T.H., Kirn D.H. Vaccinia virus and oncolytic virotherapy of cancer. Curr. Opin. Mol. Ther. 2005, 7:359-365.
182. Thorne S.H., Hwang T.H., O'Gorman W.E., Bartlett D.L., Sei S., Kanji F., Brown C., Werier J., Cho J.H., Lee D.E., Wang Y., Bell J., Kirn D.H. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 2007, 117:3350-3358.
183. Tokarska-Schlattner M., Boissan M., Munier A., Borot C., Mailleau C., Speer O., Schlattner U., Lacombe M.L. The nucleoside diphosphate kinase D (NM23-H4) binds the inner mitochondrial membrane with high affinity to cardiolipin and couples nucleotide transfer with respiration. J. Biol. Chem. 2008, 283:26198-26207.
184. Topalis D., Alvarez K., Barral K., Munier-Lehmann H., Schneider B., Véron M., Guerreiro C., Mulard L., El-Amri C., Canard B., Deville-Bonne D. Acyclic phosphonate nucleotides and human adenylate kinases: impact of a borano group on alpha-P position. Nucleosides Nucleotides Nucleic Acids 2008, 27:319-331.
185. Topalis D., Collinet B., Gasse C., Dugué L., Balzarini J., Pochet S., Deville-Bonne D. Substrate specificity of vaccinia virus thymidylate kinase. FEBS J. 2005, 272:6254-6265.
186. Topalis D., Kumamoto H., Amaya Velasco M.F., Dugué L., Haouz A., Alexandre J.A., Gallois-Montbrun S., Alzari P.M., Pochet S., Agrofoglio L.A., Deville-Bonne D. Nucleotide binding to human UMP-CMP kinase using fluorescent derivatives: a screening based on affinity for the UMP-CMP binding site. FEBS J. 2007, 274:3704-3714.
187. Tung P.P., Summers W.C. Substrate specificity of Epstein-Barr virus thymidine kinase. Antimicrob. Agents Chemother. 1994, 38:2175-2179.
188. Turk B., Awad R., Usova E.V., Björk I., Eriksson S. A pre-steady-state kinetic analysis of substrate binding to human recombinant deoxycytidine kinase: a model for nucleoside kinase action. Biochemistry 2009, 38:8555-8561.
189. Van Rompay A.R., Johansson M., Karlsson A. Phosphorylation of deoxycytidine analog monophosphates by UMP-CMP kinase: molecular characterisation of the human enzyme. Mol. Pharmacol. 1999, 56:562-569.
190. Van Rompay A.R., Johansson M., Karlsson A. Substrate specificity and phosphorylation of nucleosides and nucleosides analogs by mammalian nucleoside monophosphate kinases. Pharmacol. Ther. 2000, 87:189-198.
191. Van Rompay A.R., Johansson M., Karlsson A. Substrate specificity and phosphorylation of antiviral and anticancer nucleoside analogues by human deoxyribonucleoside kinases and ribonucleoside kinases. Pharmacol. Ther. 2003, 100:119-139.
192. Verri A., Priori G., Spadari S., Tondelli L., Focher F. Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of l-nucleoside analogues. Biochem. J. 1997, 328:317-320.
193. Vogt J., Perozzo R., Pautsch A., Prota A., Schelling P., Pilger B., Folkers G., Scapozza L., Schulz G.E. Nucleoside binding site of herpes simplex type 1 thymidine kinase analyzed by X-ray crystallography. Proteins 2000, 41:545-553.
194. Vonrheim C., Schlauderer G.J., Schulz G.E. Movie of the structural changes during a catalytic cycle of nucleoside monophosphate kinases. Structure 1995, 3:483-490.
195. Votruba I., Bernaerts R., Sakuma T., De Clercq E., Merta A., Rosenberg I., Holy A. Intracellular phosphorylation of broad-spectrum anti-DNA virus agent (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and inhibition of viral DNA synthesis. Mol. Pharmacol. 1987, 32:524-529.
196. Wagner C.R., Iyer V.V., McIntee E.J. Pronucleotides: toward the in vivo delivery of antiviral and anticancer nucleotides. Med. Res. Rev. 2000, 20:417-451.
197. Wang L., Choudhury D., Chattopadhyaya J., Eriksson S. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry 1999, 38:16993-16999.
198. Welin M., Kosinska U., Mikkelsen N., Carnrot C., Zhu C., Wang L., Eriksson S., Munch-Petersen B., Eklund H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:17970-17975.
199. Wild K., Bohner A., Aubry A., Folkers G., Schulz G.E. The three-dimensional structure of thymidine kinase from Herpes Simplex Virus type 1. FEBS Lett. 1995, 368:289-295.
200. Wild K., Bohner T., Folkers G., Schulz G.E. The structures of thymidine kinase from herpes simplex virus type 1 in complex with substrates and a substrate analogue. Protein Sci. 1997, 6:2097-2106.
201. Wu W., Bergstrom D.E., Jo Davisson V. Chemoenzymatic preparation of nucleoside triphosphates. Curr. Protoc. Nucleic Acid Chem. 2004, Chapter 13, Unit 13.2.
202. Wurth C., Kessler U., Vogt J., Schulz G.E., Folkers G., Scapozza L. The effect of substrate binding on the conformation and structural stability of herpes simplex virus type 1 thymidine kinase. Protein Sci. 2001, 10:63-73.
203. Xu Y., Sellam O., Moréra S., Sarfati R., Biondi R., Véron M., Janin J. X-ray analysis of azido-thymidine diphosphate binding to nucleoside diphosphate kinase. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:7162-7165.
204. Xu Y.W., Morera S., Janin J., Cherfils J. AlF3 mimics the transition state of protein phosphorylation in the crystal structure of nucleoside diphosphate kinase and MgADP. Proc. Natl. Acad. Sci. USA 1997, 94:3579-3584.
205. Yan H., Tsai M.-D. Nucleoside monophosphate kinases: structure, mechanism and substrate specificity. Adv. Enzymol. 1999, 73:103-134.
206. Young J.D., Yao S.Y.M., Sun L., Cass C.E., Baldwin S.A. Human equilibrative nucleoside transporter (ENT) family of nucleoside and nucleobase transporter proteins. Xenobiotica 2008, 38:995-1021.
207. Zimmermann A., Michel D., Pavic I., Hampl W., Lüske A., Neyts J., De Clerq E., Mertens T. Phosphorylation of aciclovir, ganciclovir, penciclovir and S2242 by the cytomegalovirus UL97 protein: a quantitative analysis using recombinant vaccinia viruses. Antiviral Res. 1997, 36:35-42.